Mitochondrial DNA heteroplasmy in disease and targeted nuclease‐based therapeutic approaches
Open accessThe DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
Mitochondrial DNA (mtDNA) encodes a subset of the genes which are responsible for oxidative phosphorylation. Pathogenic mutations in the human mtDNA are often heteroplasmic, where wild‐type mtDNA species co‐exist with the pathogenic mtDNA and a bioenergetic defect is only seen when the pathogenic mtDNA percentage surpasses a threshold for biochemical manifestations. mtDNA segregation during germline development can explain some of the extreme variation in heteroplasmy from one generation to the next. Patients with high heteroplasmy for deleterious mtDNA species will likely suffer from bona‐fide mitochondrial diseases, which currently have no cure. Shifting mtDNA heteroplasmy toward the wild‐type mtDNA species could provide a therapeutic option to patients. Mitochondrially targeted engineered nucleases, such as mitoTALENs and mitoZFNs, have been used in vitro in human cells harboring pathogenic patient‐derived mtDNA mutations and more recently in vivo in a mouse model of a pathogenic mtDNA point mutation. These gene therapy tools for shifting mtDNA heteroplasmy can also be used in conjunction with other therapies aimed at eliminating and/or preventing the transfer of pathogenic mtDNA from mother to child.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mitochondrial DNA mutation associated with Leber’s hereditary optic neuropathy
Wallace, D. C., Singh, G., Lott, M. T., Hodge, J. A., Schurr, T. G., Lezza, A. M. S., Elsas, L. J., & Nikoskelainen, E. K. (1988) · Science · doi:10.1126/science.3201231 · Cited by 2,440
Signal transduction by reactive oxygen species
Finkel, T. (2011) · Journal of Cell Biology · doi:10.1083/jcb.201102095 · Cited by 2,322
Bender, A., Krishnan, K. J., Morris, C. M., Taylor, G. A., Reeve, A. K., Perry, R. H., Jaros, E., Hersheson, J. S., Betts, J., Klopstock, T., et al. (2006) · Nature Genetics · doi:10.1038/ng1769 · Cited by 1,570 · cited 1×
“Accumulation of mtDNA deletions in post-mitotic tissues is also observed during normal aging [78 – 82].”
Mitochondrial DNA sequences of primates: tempo and mode of evolution
Brown, W. M., Prager, E. M., Wang, A., & Wilson, A. C. (1982) · Journal of Molecular Evolution · doi:10.1007/bf01734101 · Cited by 1,554
Mitochondrial DNA mutations and human disease
Tuppen, H. A. L., Blakely, E. L., Turnbull, D. M., & Taylor, R. W. (2010) · Biochimica et Biophysica Acta (BBA) - Bioenergetics · doi:10.1016/j.bbabio.2009.09.005 · Cited by 676 · cited 1×
“The common deletion is a 4,977-bp deletion ( D 4,977) whose breakpoint is flanked by 13-bp direct repeats [67,74,83].”
A Unique Gene Regulatory Network Resets the Human Germline Epigenome for Development
Tang, W. W. C., Dietmann, S., Irie, N., Leitch, H. G., Floros, V. I., Bradshaw, C. R., Hackett, J. A., Chinnery, P. F., & Surani, M. A. (2015) · Cell · doi:10.1016/j.cell.2015.04.053 · Cited by 670 · cited 1×
“Methodologies to isolate PGCs from human embryos still have not been successful, but protocols to isolate human PGCs from Carnegie stage 12 and onwards have been developed and allow for the investigation of the human germline [37,38].”
Bua, E., Johnson, J., Herbst, A., Delong, B., McKenzie, D., Salamat, S., & Aiken, J. M. (2006) · The American Journal of Human Genetics · doi:10.1086/507132 · Cited by 442
Specific elimination of mutant mitochondrial genomes in patient-derived cells by mitoTALENs
Bacman, S. R., Williams, S. L., Pinto, M., Peralta, S., & Moraes, C. T. (2013) · Nature Medicine · doi:10.1038/nm.3261 · Cited by 432
Self-citationEnhancing zinc-finger-nuclease activity with improved obligate heterodimeric architectures
Doyon, Y., Vo, T. D., Mendel, M. C., Greenberg, S. G., Wang, J., Xia, D. F., Miller, J. C., Urnov, F. D., Gregory, P. D., & Holmes, M. C. (2011) · Nature Methods · doi:10.1038/nmeth.1539 · Cited by 402
Kennedy, S. R., Salk, J. J., Schmitt, M. W., & Loeb, L. A. (2013) · PLoS Genetics · doi:10.1371/journal.pgen.1003794 · Cited by 363 · cited 1×
“The prevalence of mtDNA point mutations ranges between 1:5,000 and 1:500,000 [26,44].”
Cited by
Mitochondrial DNA copy number in human disease: the more the better?
Filograna, R., Mennuni, M., Alsina, D., & Larsson, N. (2021) · FEBS Letters · doi:10.1002/1873-3468.14021 · Cited by 478
Mitochondrial disorders of the OXPHOS system
Fernandez‐Vizarra, E., & Zeviani, M. (2021) · FEBS Letters · doi:10.1002/1873-3468.13995 · Cited by 305
From mitochondria to sarcopenia: role of 17β-estradiol and testosterone
Tian, X., Lou, S., & Shi, R. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1156583 · Cited by 54
“Genetic defects of mtDNA are associated with many human diseases (29).”
BackgroundThe Mitochondrial Genome in Aging and Disease and the Future of Mitochondrial Therapeutics
Saravanan, S., Lewis, C. J., Dixit, B., O’Connor, M. S., Stolzing, A., & Boominathan, A. (2022) · Biomedicines · doi:10.3390/biomedicines10020490 · Cited by 13
“The emerging role of mitochondrial health in fertility has led to more active research into both preventative and curative treatment options, including mitochondrial replacement technologies [78] and gene editing approaches [79,80], such as with directed nucleases [81] or nucleic acid therapies [82,83].”
BackgroundExogenous expression of ATP8, a mitochondrial encoded protein, from the nucleus in vivo
Begelman, D. V., Dixit, B., Truong, C., King, C. D., Watson, M. A., Schilling, B., Brand, M. D., & Boominathan, A. (2024) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2024.101372 · Cited by 5
Metadata
- Authors
- Nissanka, N., & Moraes, C. T.
- Venue
- EMBO reports
- Published
- 2020-02-19
- Volume
- 21
- Issue
- 3
- Pages
- e49612-e49612
- ISSN
- 1469-221X (ISSN-L)
- 1469-3178
- OpenAlex
- W3007098184
- Cited by
- 121
- References
- 16
- FWCI
- 3.53
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Mitochondrial DNA heteroplasmy in disease and targeted nuclease‐based therapeutic approaches. https://app.cochat.ai/papers/10.15252/embr.201949612
- The paper
- Nissanka, N., & Moraes, C. T. (2020). Mitochondrial DNA heteroplasmy in disease and targeted nuclease‐based therapeutic approaches. EMBO reports. https://doi.org/10.15252/embr.201949612
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.